Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday). [More]
Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. [More]
Medical University of Vienna study supports use of ANGLE's Parsortix system for ovarian cancer study

Medical University of Vienna study supports use of ANGLE's Parsortix system for ovarian cancer study

ANGLE plc, the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has published highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer. [More]
New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research, Scientific Partner to SU2C, announced today the formation of a Dream Team devoted to ovarian cancer research at the AACR Annual Meeting 2015, held here April 18-22. [More]
Research explores new, personalized ovarian cancer treatments

Research explores new, personalized ovarian cancer treatments

Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute, partner with UPMC CancerCenter, presented today at the American Association for Cancer Research Annual Meeting 2015. [More]
Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency - long associated with numerous diseases, e.g. autism, lung cancer, prostate cancer, and ovarian cancers - can lead to activation of the Hedgehog signaling pathway, a biomolecular pathway that plays essential roles in developing organisms and in diseases, according to new research at Rensselaer Polytechnic Institute. [More]

President Bill Clinton honored with inaugural Tina's Wish Global Women's Health Award

Tina's Wish, the only nonprofit organization dedicated exclusively to funding research for the early detection of ovarian cancer, honored President Bill Clinton with the inaugural Tina's Wish Global Women's Health Award at a reception at the Waldorf Astoria New York on April 14th. [More]
Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Nearly anyone touched by ovarian cancer will tell you: it's devastating. It's bad enough that cancer in almost 80 percent of patients reaches advanced stages before diagnosis, and that most patients are expected to die within five years. But just as painfully, roughly one quarter of women diagnosed have no warning that they are resistant to platinum-based chemotherapy, the main line of defense, nor that they will likely have 18 months to live. [More]
UAB research findings may lead to better treatment for women with HER2+ breast cancer

UAB research findings may lead to better treatment for women with HER2+ breast cancer

There are five subtypes of breast cancer, and they are distinct diseases with vastly different biologies that drastically alter their progression and responses to treatment. Understanding those differences is the starting point to a more effective, personalized treatment of breast cancer, which strikes more than 230,000 women in the U.S. each year. [More]
Women with ovarian cancer need to be tested for BRCA genes

Women with ovarian cancer need to be tested for BRCA genes

The genes BRCA1 and BRCA2 play a significant role in hereditary breast and ovarian cancers. Recent media attention has focused on American actress Angelina Jolie's decision to have her ovaries and fallopian tubes surgically removed after genetic testing for such cancers. [More]
Vermillion, Kaiser Permanente partner to enhance diagnosis, treatment of ovarian cancer

Vermillion, Kaiser Permanente partner to enhance diagnosis, treatment of ovarian cancer

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced the initiation of a strategic partnership with Kaiser Permanente's Southern California Permanente Medical Group in order to enhance the diagnosis and treatment of ovarian cancer. [More]

VolitionRx adds three new laboratory automation systems to expedite sample analysis for its large ongoing clinical trials

Using its first installed robot, VolitionRx has recently completed the analysis of a first NuQ® assay on the complete set of 4,800 blood samples for its large retrospective, symptomatic population colorectal cancer study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark. [More]
Bright Pink, David's Bridal team up to raise awareness on breast and ovarian cancer

Bright Pink, David's Bridal team up to raise awareness on breast and ovarian cancer

It's time to pucker up for a cause! Beginning today, David's Bridal will donate $1 (up to $100,000) to Bright Pink for every kiss sent on Instagram and Twitter using the hashtag #WithAKiss! [More]

Women with inherited BRCA1/2 mutations at increased risk of breast and ovarian cancers

In a study that involved more than 31,000 women who are carriers of disease-associated mutations in the BRCA1 or BRCA2 genes, researchers identified mutations that were associated with significantly different risks of breast and ovarian cancers, findings that may have implications for risk assessment and cancer prevention decision making among carriers of these mutations, according to a study in the April 7 issue of JAMA. [More]
MabVax closes $11.6 million in private placement

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health. [More]
Mayo Clinic-led researchers combine genetic variants to improve identification of women with breast cancer

Mayo Clinic-led researchers combine genetic variants to improve identification of women with breast cancer

Recent large-scale genomic analyses have uncovered dozens of common genetic variants that are associated with breast cancer. Each variant, however, contributes only a tiny amount to a person's overall risk of developing the disease. [More]
Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics, Inc. today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib). [More]
Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign. [More]
Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canadian and American health-care professionals will work together to study the effectiveness of advanced integrative oncology (AIO) treatment for patients with late stage cancer. AIO treatment includes elements of conventional and naturopathic medicine. [More]

Researchers identify potential drug molecule that kills cancer cells

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made. [More]
Advertisement
Advertisement